McKesson Europe AG (CAKFY) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
McKesson Europe AG (CAKFY) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 35/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026McKesson Europe AG (CAKFY) Gesundheitswesen & Pipeline-Uebersicht
McKesson Europe AG, a subsidiary of McKesson Corporation, is a major player in the European pharmaceutical distribution and retail pharmacy sectors. Operating through a network of wholesale branches, distribution centers, and retail pharmacies, the company provides pharmaceutical products, healthcare services, and pharmacy management solutions across multiple European countries.
Investmentthese
McKesson Europe AG presents a complex investment case. The company's extensive distribution network and retail pharmacy presence across Europe provide a stable revenue base. However, the company's negative profit margin of -0.5% and a high P/E ratio of -73.27 raise concerns about profitability. Growth catalysts include expanding e-commerce and home care services. Key risks include regulatory changes in the pharmaceutical industry and competition from other distributors. Investors should closely monitor the company's efforts to improve profitability and adapt to evolving market dynamics.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Operates approximately 2,000 owned pharmacies and supports 8,000 members in its brand partnership program, indicating a strong retail presence.
- Serves approximately 40,000 pharmacies and hospitals through its 90 wholesale branches, showcasing a wide distribution network.
- Profit Margin is -0.5%, indicating potential challenges in achieving profitability.
- P/E ratio is -73.27, reflecting the company's current earnings situation.
- Beta of 0.13 suggests low volatility compared to the overall market.
Wettbewerber & Vergleichsunternehmen
Staerken
- Extensive distribution network across Europe.
- Strong retail pharmacy presence with the Lloyds Pharmacy brand.
- Established relationships with pharmacies and hospitals.
- Part of the global McKesson Corporation.
Schwaechen
- Negative profit margin.
- High P/E ratio.
- Exposure to regulatory changes in the pharmaceutical industry.
- Dependence on the European market.
Katalysatoren
- Ongoing: Expansion of e-commerce and home care services to drive revenue growth.
- Ongoing: Strategic partnerships and acquisitions to expand market presence.
- Ongoing: Development of value-added services for pharmacists to strengthen customer relationships.
- Ongoing: Geographic expansion within Europe to increase market share.
- Ongoing: Focus on specialty pharmaceuticals to capitalize on the growing market.
Risiken
- Ongoing: Increasing competition from other pharmaceutical distributors and retail pharmacy chains.
- Potential: Pricing pressures from governments and healthcare providers.
- Potential: Economic downturn in Europe affecting consumer spending on healthcare products.
- Potential: Disruptions in the supply chain impacting the availability of pharmaceutical products.
- Potential: Regulatory changes in the pharmaceutical industry impacting pricing and distribution.
Wachstumschancen
- Expansion of E-commerce and Home Care Services: McKesson Europe AG can capitalize on the growing demand for online pharmacy services and home healthcare. The e-commerce market in Europe is projected to reach $200 billion by 2028, offering a significant growth opportunity. By expanding its online platform and home care offerings, McKesson Europe AG can reach a wider customer base and increase revenue streams. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with healthcare providers and acquiring smaller pharmacy chains can expand McKesson Europe AG's market presence and service offerings. The company can leverage partnerships to offer integrated healthcare solutions and enhance customer loyalty. Timeline: Ongoing.
- Development of Value-Added Services for Pharmacists: McKesson Europe AG can further develop and expand its services for pharmacists, such as pharmacy cooperation programs and management tools. By providing value-added services, the company can strengthen its relationships with pharmacists and increase its market share. Timeline: Ongoing.
- Geographic Expansion within Europe: Expanding into new geographic markets within Europe can drive growth for McKesson Europe AG. By entering underserved markets or acquiring existing pharmacy chains, the company can increase its revenue and market share. Timeline: Ongoing.
- Focus on Specialty Pharmaceuticals: The market for specialty pharmaceuticals is growing rapidly, driven by the development of new and innovative therapies. McKesson Europe AG can focus on distributing specialty pharmaceuticals and providing related services to capitalize on this trend. Timeline: Ongoing.
Chancen
- Expansion of e-commerce and home care services.
- Strategic partnerships and acquisitions.
- Development of value-added services for pharmacists.
- Growth in the specialty pharmaceuticals market.
Risiken
- Increasing competition from other pharmaceutical distributors and retail pharmacy chains.
- Pricing pressures from governments and healthcare providers.
- Economic downturn in Europe.
- Disruptions in the supply chain.
Wettbewerbsvorteile
- Extensive Distribution Network: Operates a large network of wholesale branches and distribution centers across Europe.
- Strong Retail Pharmacy Presence: Operates a significant number of retail pharmacies under the Lloyds Pharmacy brand.
- Established Brand Reputation: Has a long history and established brand reputation in the European pharmaceutical market.
- Part of McKesson Corporation: Benefits from the resources and expertise of its parent company, McKesson Corporation.
Ueber CAKFY
McKesson Europe AG, formerly known as Celesio AG, traces its roots back to 1835 and is headquartered in Stuttgart, Germany. The company changed its name in September 2017 after becoming a subsidiary of McKesson Corporation. McKesson Europe AG operates in the pharmaceutical and healthcare sectors, providing logistics and other services. It has two primary divisions: Pharmaceutical Distribution and Retail Pharmacy. The Pharmaceutical Distribution division is involved in the wholesale of pharmaceutical and healthcare products, serving approximately 40,000 pharmacies and hospitals through 90 wholesale branches and operating 70 distribution centers across Europe. The Retail Pharmacy division operates around 2,000 owned pharmacies and has approximately 8,000 members in its brand partnership program. This division provides outpatient drug, e-commerce, and home care services, primarily under the Lloyds Pharmacy brand in countries like Belgium, Ireland, Italy, and the United Kingdom. The division offers traditional prescription drugs, over-the-counter products, and medical services. McKesson Europe AG also provides services for pharmacists, including the organization and management of pharmacy cooperation programs in Great Britain, France, Portugal, and Belgium.
Was das Unternehmen tut
- Wholesale distribution of pharmaceutical products to pharmacies and hospitals.
- Operation of retail pharmacies under the Lloyds Pharmacy brand.
- Provision of outpatient drug services.
- E-commerce services for pharmaceutical products.
- Home care services.
- Management of pharmacy cooperation programs.
- Distribution of traditional prescription drugs and over-the-counter products.
- Provision of medical services.
Geschaeftsmodell
- Generates revenue through the wholesale distribution of pharmaceutical products.
- Earns revenue from the operation of retail pharmacies and the sale of prescription and over-the-counter drugs.
- Provides e-commerce services, generating revenue through online sales.
- Offers home care services, generating revenue through service fees.
Branchenkontext
McKesson Europe AG operates in the competitive pharmaceutical distribution and retail pharmacy industry. The industry is characterized by increasing demand for healthcare services, driven by an aging population and rising prevalence of chronic diseases. Key trends include the growth of e-commerce and home care services, as well as increasing regulatory scrutiny. McKesson Europe AG competes with other major distributors and retail pharmacy chains, such as ABCZF (All American Healthcare Corp), ANHGY (Anthem Inc), ARHCF (Arches Health Care, Inc.), ASPHF (Aspen Healthcare Inc), and DCHPF (Direct Communication Healthcare).
Wichtige Kunden
- Pharmacies: Supplies pharmaceutical products to approximately 40,000 pharmacies.
- Hospitals: Distributes pharmaceutical products to hospitals.
- Individual Patients: Serves patients through its retail pharmacies and e-commerce platform.
- Pharmacists: Provides services and support to pharmacists through its pharmacy cooperation programs.
Finanzdaten
Chart & Info
McKesson Europe AG (CAKFY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CAKFY verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CAKFY.
Kursziele
Wall-Street-Kurszielanalyse fuer CAKFY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CAKFY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Tilo Köster
Managing Director
Information on Tilo Köster's background is limited. He currently serves as Managing Director of McKesson Europe AG, overseeing the company's operations across its Pharmaceutical Distribution and Retail Pharmacy divisions. His responsibilities include managing a large workforce of over 26,000 employees and driving the company's strategic initiatives in the European market.
Erfolgsbilanz: Due to limited information, Tilo Köster's specific achievements and strategic decisions at McKesson Europe AG are not readily available. His leadership is focused on navigating the complexities of the European pharmaceutical market and driving growth through strategic partnerships and operational efficiencies.
CAKFY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that McKesson Europe AG (CAKFY) may not meet the minimum financial or regulatory requirements for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited reporting requirements, leading to less transparency for investors compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with distressed financials, shell corporations, or those that choose not to comply with stricter reporting standards.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited Transparency: OTC Other companies often have minimal reporting requirements, making it difficult to assess their financial health.
- Low Liquidity: Low trading volume can lead to wide bid-ask spreads and difficulty in executing trades.
- Price Volatility: The lack of liquidity can result in significant price swings.
- Potential for Fraud: The lower regulatory oversight increases the risk of fraudulent activities.
- Delisting Risk: The company may not meet the requirements for listing on higher tiers or major exchanges.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC Other companies.
- Consult with a financial advisor.
- Check for any legal or regulatory issues.
- Subsidiary of McKesson Corporation: Being a subsidiary of a well-established company like McKesson Corporation provides some level of assurance.
- Operational Business: The company has a clear business model and operates in the pharmaceutical distribution and retail pharmacy sectors.
- Employee Count: The company employs over 26,000 people, suggesting a significant operational scale.
- Long Operating History: The company was founded in 1835, indicating a long history in the industry.
CAKFY Healthcare Aktien-FAQ
What are the key factors to evaluate for CAKFY?
McKesson Europe AG (CAKFY) currently holds an AI score of 35/100, indicating low score. Key strength: Extensive distribution network across Europe.. Primary risk to monitor: Ongoing: Increasing competition from other pharmaceutical distributors and retail pharmacy chains.. This is not financial advice.
How frequently does CAKFY data refresh on this page?
CAKFY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CAKFY's recent stock price performance?
Recent price movement in McKesson Europe AG (CAKFY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Extensive distribution network across Europe.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CAKFY overvalued or undervalued right now?
Determining whether McKesson Europe AG (CAKFY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CAKFY?
Before investing in McKesson Europe AG (CAKFY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CAKFY to a portfolio?
Potential reasons to consider McKesson Europe AG (CAKFY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Extensive distribution network across Europe.. Additionally: Strong retail pharmacy presence with the Lloyds Pharmacy brand.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CAKFY?
Yes, most major brokerages offer fractional shares of McKesson Europe AG (CAKFY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CAKFY's earnings and financial reports?
McKesson Europe AG (CAKFY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CAKFY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available sources and may be limited due to the company's OTC listing.
- Financial data is as of the latest available reporting period.